Medifocus, Inc. Featured in Article in "BioTuesdays" Titled, "Medifocus Readies Marketing Expansion of Prolieve"

COLUMBIA, MD and TORONTO, ON--(Marketwired - Jul 8, 2014) - Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it is featured in today's BioTuesday titled, "Medifocus Readies Market Expansion of Prolieve." Prolieve is a FDA-Approved commercial device for the treatment of symptoms caused by the enlargement of the prostate, which is known as Benign Prostatic Hyperplasia (BPH). The full article can be read on www.biotuesdays.com

In the article, Dr. Augustine Y. Cheung, CEO of Medifocus, Inc. is interviewed where he details Medifocus' progress and accomplishments in setting the infrastructure and base to execute its marketing expansion of Prolieve worldwide. The prevalence of BPH increases with age, and over 50% of all men over the age of 50 have BPH. The market size for prescription drug therapy for BPH is estimated to be $4 billion a year. In addition, if you also include patients on "watchful waiting," meaning patients suffering from BPH symptoms, however they elect not to take drugs or minimal invasive surgery, the market could double to $8 billion!

About BIOTUESDAYS.COM

BioTuesdays.com is an independent business and investing news blog focused on the healthcare space. At BioTuesdays, we believe there is a plethora of great technologies and investment stories that have yet to be fully recognized due to a lack of traditional media coverage of small and medium sized healthcare companies. We hope to prove that each and every Tuesday.

About Medifocus, Inc.

Medifocus develops and commercializes minimally invasive, unique focused heat treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, or Benign Prostatic Hyperplasia ("BPH").

The Company owns two technology platforms with comprehensive US and international patent protection: The "Endo-thermotherapy Platform" and the "Adaptive Phased Array Microwave Focusing Platform." Based on these platform technologies, the Company has developed two advanced therapeutic products: the Prolieve® system for the treatment of BPH, and the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer.

The U.S. FDA-approved Prolieve® System (www.prolieve.com) is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The heating plus dilatation treatment offered by the Prolieve® System is the only minimally invasive treatment which offers both immediate and long term relief of symptoms due to enlarged prostate (BPH) in men. The clinical indication received for Prolieve from the FDA is an "alternative to drug therapy." With this indication, the Prolieve® System is a revenue generating device based product which can have the potential of catering to the $8 billion non-surgical prescription drug therapy market for treatment of BPH.